Portal de investigação
Real-world biologics response and super-response in the International Severe Asthma Registry cohort
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Denton, Eve
- Hew, Mark
- Peters, Matthew J.
- Upham, John W.
- Bulathsinhala, Lakmini
- Tran, Trung N.
- Martin, Neil
- Bergeron, Celine
- Al-Ahmad, Mona
- Altraja, Alan
- Larenas-Linnemann, Desiree
- Murray, Ruth
- Celis-Preciado, Carlos Andres
- Al-Lehebi, Riyad
- Belhassen, Manon
- Bhutani, Mohit
- Bosnic-Anticevich, Sinthia Z.
- Bourdin, Arnaud
- Brusselle, Guy G.
- Busby, John
- Canonica, Giorgio Walter
- Heffler, Enrico
- Chapman, Kenneth R.
- Charriot, Jeremy
- Christoff, George C.
- Chung, Li Ping
- Cosio, Borja G.
- Cote, Andreanne
- Costello, Richard W.
- Cushen, Breda
- Fingleton, James
- Gibson, Peter G.
- Heaney, Liam G.
- Huang, Erick Wan-Chun
- Iwanaga, Takashi
- Jackson, David J.
- Koh, Mariko Siyue
- Lehtimaki, Lauri
- Maspero, Jorge
- Mahboub, Bassam
- Menzies-Gow, Andrew N.
- Mitchell, Patrick D.
- Papadopoulos, Nikolaos G.
- Papaioannou, Andriana I.
- Perez-de-Llano, Luis
- Perng, Diahn-Warng
- Pfeffer, Paul E.
- Popov, Todor A.
- Porsbjerg, Celeste M.
- Rhee, Chin Kook
- Roche, Nicolas
- Sadatsafavi, Mohsen
- Salvi, Sundeep
- Schmid, Johannes Martin
- Sheu, Chau-Chyun
- Sirena, Concetta
- Torres-Duque, Carlos A.
- Salameh, Laila
- Patel, Pujan H.
- Ulrik, Charlotte Suppli
- Wang, Eileen
- Wechsler, Michael E.
- Price, David B.
- ISAR LUMINANT Working Grp
Unidades de investigação
Abstract
Background: Biologic asthma therapies reduce exacerbations and long-term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real-world population of adults with severe asthma. Methods: Adults in the International Severe Asthma Registry (ISAR) with >= 24 weeks of follow-up were grouped into those who did, or did not, initiate biologics (anti-IgE, anti-IL5/IL5R, anti-IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV1) increase by >= 100 mL, improved asthma control, annualized exacerbation rate (AER) reduction >= 50%, and any LTOCS dose reduction. Super-response criteria were: FEV1 increase by >= 500 mL, new well-controlled asthma, no exacerbations, and LTOCS cessation or tapering to <= 5 mg/day. Results: 5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non-initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super-responses. Responses/super-responses were more frequent in biologic initiators than in non-initiators; nevertheless, similar to 40-50% of initiators did not meet response criteria. Conclusions: Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non-initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super-responses in all outcome domains, 40-50% did not meet the response criteria.
© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Dados da publicação
- ISSN/ISSNe:
- 0105-4538, 1398-9995
- Tipo:
- Article
- Páginas:
- 2700-2716
- DOI:
- 10.1111/all.16178
ALLERGY Wiley-Blackwell Publishing Ltd
Documentos
- Não há documentos
Filiações
Keywords
- asthma; biologics; clinical response; International Severe Asthma Registry (ISAR); monoclonal antibodies; super-responders
Campos de estudo
Proyectos asociados
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (EPI-ASTHMA) - NCT05169619
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (EPI-ASTHMA) . AstraZeneca . 2021
Effect of a Mobile App on Improving Asthma Control in Adolescents and Adults With Persistent Asthma: A Pilot Randomized Multicentre, Superiority Clinical Trial (mINSPIRERS) - NCT05129527
Investigador Principal: João de Almeida Lopes da Fonseca
Ensaio Clínico Académico (mINSPIRERS) . 2021
Utilização em estudos observacionais do Registo de Asma Grave Portugal.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Observacional Académico (RAG) . 2020
Clinical Research Collaboration Severe Heterogenous Asthma Research collaboration, Patient-centered (CRC SHARP).
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (SHARP) . European Respiratory Society . 2021
Multidimensional phenotyping of severe asthma patients and its impact on disease control and therapeutic response - analysis from the Portuguese Severe Asthma Registry.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (RAG-SPP-GSK) . SPPneumologia . 2022
BREATHE - An oBservational, pRimary data study to characterize severe AsThma pHenotypes and assEss disease burden across the EUCAN region.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (RAG-AZ-BREATHE) . AstraZeneca . 2022
Efficiency in Spine Care ? Assessing outcomes and costs to inform healthcare improvement
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2022
Use of secondary data, health technology assessment methods and economic modelling applied to penicillin allergy
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Using different data sources for the identification of asthma patients and those at high risk of adverse outcomes
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Phenotypes of Chronic Diseases of the Airways: Towards Multidimensional Data -Driven Profiling
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Citar a publicação
Denton E,Hew M,Peters MJ,Upham JW,Bulathsinhala L,Tran TN,Martin N,Bergeron C,Al M,Altraja A,Larenas D,Murray R,Celis CA,Al R,Belhassen M,Bhutani M,Bosnic SZ,Bourdin A,Brusselle GG,Busby J,Canonica GW,Heffler E,Chapman KR,Charriot J,Christoff GC,Chung LP,Cosio BG,Cote A,Costello RW,Cushen B,Fingleton J,Fonseca JA,Gibson PG,Heaney LG,Huang EW,Iwanaga T,Jackson DJ,Koh MS,Lehtimaki L,Maspero J,Mahboub B,Menzies AN,Mitchell PD,Papadopoulos NG,Papaioannou AI,Perez L,Perng D,Pfeffer PE,Popov TA,Porsbjerg CM,Rhee CK,Roche N,Sadatsafavi M,Salvi S,Schmid JM,Sheu C,Sirena C,Torres CA,Salameh L,Patel PH,Ulrik CS,Wang E,Wechsler ME,Price DB,ISAR LUMINANT Working GRP. Real-world biologics response and super-response in the International Severe Asthma Registry cohort. Allergy. 2024. 79. (10):p. 2700-2716. IF:12,400. (1).
